Navigation Links
Common osteoporosis drugs are associated with a decrease in risk of breast cancer
Date:3/2/2010

SEATTLE Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer.

The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program at Fred Hutchinson Cancer Research Center.

"This large study provides new evidence that the use of bisphosphonates is associated with a potentially important reduction in breast cancer risk," Newcomb said.

The protective effect was observed only among women who were not obese. "Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk," Newcomb said.

The way in which these drugs may prevent breast cancer is not known, but several research observations may be relevant. "These drugs may affect cell function and be important in cell growth and death specifically the death of tumors or even premalignant disease," Newcomb said. Researchers have found that some kinds of bisphosphonates directly cause tumor apoptosis (cellular suicide), inhibit angiogenesis (prevent tumors from establishing a blood supply) and prevent tumor-cell adhesion (the ability of cancer cells to bind to one another).

The study involved nearly 6,000 Wisconsin women, aged 20 to 69. Half had been diagnosed with invasive breast cancer and, for comparison purposes, half had not. The women were interviewed about their bone health their history of fractures, whether they'd been diagnosed with osteoporosis and their history of bisphosphonate use.

Breast cancer risk factors such as first-degree family history of the disease, age at first birth, postmenopausal hormone use and body mass index were accounted for in the analysis. "Because we were able to account for important cofounders, these findings may reflect real benefits due to the anti-tumor mechanisms of these medications," the authors wrote.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
2. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
3. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
4. Migraine More Common in Women with MS
5. New therapeutic target for most common solid cancer in childhood?
6. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
7. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
8. A common cholesterol drug fights cataracts, too
9. Adapting to clogged airways makes common pathogen resist powerful drugs
10. Metabolite common among cancers
11. Nutrition Management Services Company Announces Decision to Deregister its Class A Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... For many women, getting birth control ... contraceptive deserts , meaning they either don’t have access to a health care facility or ... rural and remote regions of the United States or for many who are faced with ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... San Mateo, CA (PRWEB) , ... ... ... Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science ... manuscript leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry ...
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, ... device company, is pleased to announce that the ... investment of Panther Orthopedics, Inc., a ... dynamic fixation solutions for orthopedic extremity applications.  ... to expand rapidly, primarily due to procedure volume ...
(Date:3/28/2017)... 2017  Rosen Law Firm, a global investor rights ... lawsuit on behalf of purchasers of Kitov Pharmaceutical Holdings ... traceable to Kitov,s initial public offering on or about ... market from November 20, 2015 through February 3, 2017, ... to recover damages for Kitov investors under the federal ...
(Date:3/28/2017)... -- Summary GBI Research,s ... Key Component of Multichannel Marketing" provides a comprehensive ... the digital age. While the pharmaceutical industry ... it has been much slower to adopt technology ... channels and methods. However, the decreasing effectiveness of ...
Breaking Medicine Technology: